Dpc

Quick links to important sections

Dpc

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dpc

Property Description
Active ingredient Bromhexine, Chlorpheniramine, Dextromethorphan, Phenylpropanolamine
Form Oral Liquid (Syrup or Suspension), Tablet, Capsule
Pharmacological class Multi-Component Respiratory Agent (Mucolytic, Antihistamine, Antitussive, Decongestant)
Common use Symptomatic relief of cold, cough, and allergy manifestations
Origin Synthetic chemical entities

What Type of Medicine is DPC? (Definition, Class, and Composition)

DPC is a synthetic, fixed-dose combination drug classified as a Multi-Component Respiratory Agent. It is designed for oral administration and available in dosage forms such as an oral liquid or a tablet, intended to provide systemic relief from respiratory and allergic symptoms.

The medicine's identity is defined by its four active ingredients: Bromhexine, Chlorpheniramine, Dextromethorphan, and Phenylpropanolamine. This unique combination structure places DPC apart from single-ingredient cough or allergy solutions. The co-administration of agents from different pharmacological classes provides more comprehensive symptomatic relief than a single agent alone. The formula intentionally groups a mucolytic agent, an antihistamine, a central antitussive (cough suppressant), and a systemic decongestant (sympathomimetic amine).


The General Purpose of DPC's Components (High-Level Therapeutic Role)

The general purpose of DPC is to achieve broad-spectrum, symptomatic relief by treating a complex of discomforting symptoms in a unified manner. This multi-target approach is essential in scenarios like managing an acute cold that involves both a congested nose and a persistent cough with thick mucus.

The individual components contribute to the collective function: Bromhexine thins viscid mucus to promote airway clearance; Chlorpheniramine reduces allergic manifestations like sneezing; Dextromethorphan helps control the persistent urge to cough; and Phenylpropanolamine reduces nasal congestion and swelling, thereby aiding respiration. The integration of a secretolytic agent alongside the antitussive is a distinct feature of this combination, designed to thin secretions while simultaneously suppressing the cough reflex.

Regulatory References

  1. NIH/StatPearls Dextromethorphan Guaifenesin

What side effects are possible with Dpc?

Possible Side Effects and Safety Information

The officially documented safety profile for Dpc, a multi-component respiratory agent, highlights adverse reactions primarily categorized by their effect on specific body systems and their frequency of occurrence, as defined by regulatory documents.

Frequency-Classified Adverse Reactions

The most frequently documented effects often involve the nervous system. Sedation or drowsiness are classified as Very Common in regulatory labeling, stemming primarily from the antihistamine component. Other reactions classified as Common include dizziness, headache, nausea, and dry mouth. Uncommon effects include non-severe rash and other hypersensitivity reactions.

System-Organ-Class (SOC) Safety Concerns

Adverse reactions are formally grouped by the system-organ class affected:

  • Nervous System Disorders: Sedation, drowsiness, dizziness, and excitability.
  • Gastrointestinal Disorders: Nausea, vomiting, and dry mouth.
  • Cardiac Disorders: Tachycardia (fast heart rate) and palpitations (Phenylpropanolamine component).
  • Skin and Subcutaneous Tissue Disorders: Rash, urticaria, and rare, documented risks of severe cutaneous adverse reactions (SCARs).

Serious Adverse Reactions and Restrictions

Regulatory safety information documents rare but serious risks, including anaphylaxis and the potential for hypertensive crisis or hemorrhagic stroke associated with the sympathomimetic component. The label also notes the risk of Serotonin syndrome when the antitussive component is combined with certain interacting agents. Use is restricted in patients with severe uncontrolled hypertension or severe coronary artery disease.

Population-Specific Notes

Official labels indicate that older adults may be more susceptible to CNS effects and sympathomimetic effects. Furthermore, official safety notes suggest caution in patients with severe renal or hepatic impairment due to potential changes in component clearance.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes a potential for serious adverse effects following the ingestion of an overdose of Dpc (Amoxicillin). Symptoms may range from common gastrointestinal distress to more severe complications affecting the renal and nervous systems.


Documented Overdose Presentations

Overdose presentations typically include pronounced gastrointestinal symptoms, such as nausea, vomiting, and diarrhea. Of particular concern are reports of crystalluria, a condition characterized by cloudy or bloody urine and greatly decreased frequency or amount of urination, which can lead to kidney damage and even renal failure.

In severe cases, Central Nervous System (CNS) effects such as seizures have been reported. The risk of crystalluria and subsequent renal injury is increased with the ingestion of large doses and in patients who already have impaired kidney function. This complication has been observed in both adult and pediatric populations.


Required Emergency Actions

Immediate medical assessment is required following any suspected overdose, regardless of whether any symptoms are present. Do not wait for symptoms to develop. Contact a healthcare professional, hospital emergency department, or a regional poison control centre immediately.

Immediate emergency services should be called if an individual who has taken an overdose has collapsed, has had a seizure, has trouble breathing, or cannot be awakened. Clinical management typically involves discontinuing the drug and maintaining adequate fluid intake to help reduce the risk of crystalluria.

Therapeutic Uses of Dpc

What DPC Treats: Main Uses and Benefits

DPC is a multi-component agent used in situations involving certain distressing symptoms, applied across domains where additional symptomatic support is needed. This strategy is relevant for the symptomatic management of respiratory illness.

The medication is commonly used to help with symptom clusters associated with acute cold or flu-like syndromes, including persistent coughing, nasal congestion and stuffiness, excessive viscid mucus, and allergic manifestations such as sneezing and a runny nose. The primary purpose is to provide support that helps ease the overall symptom burden. This approach helps address symptom clusters that interfere with daily comfort.

Relief from Congestion and Airway Secretions

This therapeutic area addresses symptoms related to inflammatory or irritative states that create noticeable physiological strain. The medication is applied in addressing symptoms that relate to thickened mucus and nasal stuffiness, and may assist with maintaining functional stability during respiratory discomfort. DPC supports the patient during difficult episodes by easing the distress of persistent coughing and supports general well-being during symptomatic phases.


Quick Fact: Relief for Multi-Symptom Cold DPC is generally considered relevant for conditions characterized by periods of heightened symptoms where multiple respiratory and allergic manifestations occur together, requiring supportive relief across several symptom axes.

Regulatory References

  1. NIH MedlinePlus overview on combination products

Eligibility and Restrictions for Use

Official Population Eligibility for DPC

Official regulatory documents strictly define the populations permitted to use DPC (Bromhexine, Chlorpheniramine, Dextromethorphan, Phenylpropanolamine) and those for whom use is prohibited, primarily based on contraindications related to the four-component combination.


Populations Contraindicated for Use

Use of DPC is absolutely contraindicated by regulatory agencies for individuals who:

  • Have known hypersensitivity to any component.
  • Are currently taking, or have recently stopped (within 14 days), a Monoamine Oxidase Inhibitor (MAOI).
  • Have severe hypertension or severe coronary artery disease.
  • Have conditions such as narrow-angle glaucoma or urinary retention.

Age and Physiological Status Restrictions

Age-related eligibility is restricted, with the medicine generally not recommended for use in children under four years of age, aligning with standard caution for multi-component cold and cough agents. For adults and adolescents, use is permitted under standard labeled conditions.

Pregnancy and lactation eligibility is defined as not recommended unless considered essential, due to potential risk from the combination and the possible secretion of components into breast milk.

Caution is required in patients with severe hepatic impairment, severe renal impairment, a history of gastric ulceration, or uncontrolled diabetes mellitus.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes the officially documented interactions for Dpc, as established by regulatory authorities. This information is intended to describe the drug's interaction profile and is not a substitute for clinical advice.

Regulatory-Defined Interaction Categories

The most significant interactions involve the metabolic enzyme CYP3A4 and the efflux transporter P-glycoprotein (P-gp).

Interaction Type Examples of Interacting Substances
Contraindicated Combinations Strong CYP3A4 Inducers (e.g., Rifampin, St. John's Wort); Select QTc-prolonging agents
Exposure Modifiers Strong CYP3A4 Inhibitors (e.g., Itraconazole); P-gp Inhibitors
Pharmacodynamic Effects CNS depressants (additive sedation); Other QTc-prolonging agents (additive effect)

Co-administration of strong CYP3A4 inhibitors (like Itraconazole) significantly increases Dpc exposure, which may necessitate regulatory monitoring. Conversely, co-administration with strong CYP3A4 inducers (like Rifampin) is contraindicated due to severe reduction in Dpc levels, resulting in loss of effectiveness. Dpc also inhibits P-glycoprotein, which can increase the exposure of co-administered P-gp substrates, such as Digoxin. Additionally, Dpc may require specific administration timing relative to antacids (e.g., separating doses by four hours) to maintain adequate absorption. Avoidance of Grapefruit Juice is also documented due to its impact on Dpc metabolism.

Mechanism of Action

Targeting Neurotransmitter and Histamine-Mediated Vascular Tone

This mechanism modulates vascular permeability and fluid transudation through coordinated action. Chlorpheniramine blocks the Histamine H1 receptor, inhibiting signaling that drives vasodilation. Concurrently, Phenylpropanolamine triggers the release of Norepinephrine to activate alpha1-adrenergic receptors, which induces localized vasoconstriction in the respiratory lining. These coordinated actions result in decreased mucosal edema and reduced glandular fluid output.

Central Modulation of the Cough Reflex Arc

The drug influences the central nervous system by modulating signals within the brainstem's Cough Center via its antitussive component, Dextromethorphan. By binding to receptors like the Sigma-1 receptor, this mechanism elevates the threshold of excitation necessary to trigger the involuntary expulsion reflex, resulting in the suppression of central reflex arc activity.

Physicochemical Alteration of Secretions and Clearance

This mechanism, driven by Bromhexine, involves a direct, physicochemical action on the bronchial secretions. It works by disrupting the structural integrity of acid mucopolysaccharide fibers, the components that govern mucus viscosity. The resulting decrease in mucus viscosity and increase in fluidity facilitates mucociliary apparatus transport and mechanical clearance of thickened material from the airways.

Dosage and Administration Information

Official Instructions for Use

Administration of Dpc must strictly follow the conditions detailed in the drug's official labeling. These instructions define the standardized procedure for safe and effective use.

Procedural Requirements

Administration Aspect Official Instruction in Labeling
Route of Administration Oral
Tablet Condition The tablet must be swallowed whole and not chewed, crushed, or broken.
Timing Relative to Meals Must be taken with food.
Dosing Rules Use only the exact dose and for the specific duration prescribed by a healthcare professional.

Detailed Usage Protocol

The correct use of this medicine is structured by the following mandatory steps outlined in the official documentation:

  1. Take the prescribed quantity of the drug (the dose).
  2. Take the medication in conjunction with a meal.
  3. The tablet must be swallowed intact. Do not attempt to alter the tablet form before ingestion.
  4. Continue the use of the medicine only for the duration specified by the prescription.

This protocol ensures the medicine is administered as intended by its formulation, maintains the correct timing in the digestive process, and adheres precisely to the dose and length of treatment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Dpc

This overview explains the types of official research that have explored the use of Dpc, focusing on what was studied and what remains uncertain, based on data available from regulatory and peer-reviewed sources.


Evidence for Symptomatic Relief in Multi-Symptom Respiratory Illnesses

Research for Dpc was evaluated in short-term Randomized Controlled Trials (RCTs). These studies were applied in research contexts involving fluctuating or unstable symptoms characteristic of conditions associated with acute or disruptive episodes like acute colds or flu-like syndromes. Researchers explored the four-component fixed-dose drug by comparing it against an inactive control, known as a placebo, or sometimes against single medications containing just one of Dpc’s active ingredients.

The studies tracked patient-reported outcomes describing perceived discomfort, with research examining symptom intensity or variability across scales for cough, nasal congestion, the perception of viscid mucus, and allergic manifestations like sneezing. The research examined these outcomes reflecting daily functioning or activity level.


Duration of Study and Follow-up Data

The research for Dpc primarily examines short-term symptom changes. Since Dpc was evaluated in conditions associated with acute or disruptive episodes, most clinical trials observed responses over defined time intervals lasting only 3 to 7 days.

Long-term effects are not fully established because the evidence does not track durability of response or the impact of repeated use over extended periods. Therefore, findings describe group patterns, not long-term individual outcomes.


Evidence Gaps and Research Uncertainties

One key area of research uncertainty is the specific simultaneous contribution of all four active ingredients. While research describes the features of the component drug classes (mucolytic, antihistamine, antitussive, decongestant), the combined fixed-dose approach requires its own evaluation.

The primary limitation remains the short follow-up durations and the reliance on subjective patient-reported outcomes. This type of research provides context but research does not determine whether an individual will respond similarly, as study results reflect the specific conditions under which they were conducted.

Key Studies & References

  1. National Institutes of Health (NIH) MedlinePlus: Overview on Combination Drug Products and Symptomatic Management
  2. National Institutes of Health (NIH) MedlinePlus: General Drug Information and Pharmacological Consensus

Frequently Asked Questions (FAQ)

Common questions about Dpc (FAQ)

Q: Is Dpc the same kind of drug as [Similar Drug Name]?

A: Dpc is classified as a multi-component respiratory agent because it is a fixed-dose combination of four active ingredients: a mucolytic, an antihistamine, an antitussive, and a systemic decongestant. This specific four-component structure is what defines it, distinguishing it from medications that contain only one or two ingredients for similar symptoms.


Q: Can Dpc cause weight gain or loss?

A: Official regulatory documents categorize common and very common side effects associated with Dpc, such as sedation, dizziness, and nausea. Changes in body weight (gain or loss) are not listed among the adverse reactions categorized as Very Common, Common, or Uncommon in the official product information.


Q: Is it normal to feel a bit dizzy when first starting Dpc?

A: Dizziness is listed as a Common side effect in the official product information, meaning it is frequently reported. Official information does not specify if this is more likely during the initial phase of treatment or during sustained use.


Q: What happens if I miss a dose of Dpc?

A: Official instructions for use emphasize that Dpc should only be used at the exact dose and for the specific duration prescribed. However, the regulatory documentation does not provide standardized protocol for managing a missed dose.


Q: Can Dpc make me feel tired during the day?

A: Sedation and drowsiness are classified as Very Common side effects of Dpc, primarily due to the antihistamine component. Since these effects are frequently reported, they can potentially affect alertness and daily functioning.


Q: Do I need to change my diet while on Dpc?

A: Official administration instructions state that Dpc must be taken with food. Furthermore, regulatory warnings document the need to avoid Grapefruit Juice because it can interfere with the way the body metabolizes the drug.


Q: Will Dpc affect my ability to drive or operate machinery?

A: Because sedation and drowsiness are classified as Very Common side effects, the official safety profile advises caution regarding activities that require full mental alertness, such as driving or operating heavy machinery.


Q: What's the difference between Dpc and other drugs for the same condition?

A: Dpc is defined by its fixed combination of four active ingredients, categorized as a Multi-Component Respiratory Agent. This approach is intended to provide comprehensive symptomatic relief by simultaneously targeting mucus thickness, allergic symptoms, cough, and nasal congestion, which distinguishes it from single-ingredient treatments.


Q: Does Dpc have any known effects on mood or anxiety?

A: The official safety summary lists nervous system adverse reactions, including sedation, drowsiness, and excitability. Specific effects on mood or anxiety are not detailed in the available official safety summaries.


Q: How long until the full benefit of Dpc is usually reached?

A: The clinical trials for Dpc were primarily short-term, tracking patient responses and symptom changes over defined intervals lasting only between 3 and 7 days. These studies focused on acute symptom relief.


Q: Can people with liver issues take Dpc?

A: Official eligibility criteria indicate that caution is required when prescribing Dpc to patients who have severe hepatic impairment (severe liver issues). This is due to the potential for changes in how the drug’s components are processed and cleared by the body.


Q: Will Dpc interfere with my birth control pills?

A: The official interaction profile details risks involving metabolic enzymes (CYP3A4) and drug transporters (P-gp), but oral contraceptives or birth control pills are not specifically named as interacting combinations in the regulatory summary.


Q: Are there certain times of day that Dpc is best taken?

A: Official administration instructions require that Dpc be taken in conjunction with a meal. The regulatory information does not specify a recommended time of day (such as morning or night) for administration.


Q: How will I know if Dpc is working for my condition?

A: The research for Dpc tracked improvements in patient-reported symptoms, such as the intensity of cough, nasal congestion, thick mucus perception, and sneezing. These changes were used as primary indicators of effectiveness in the clinical studies.


Q: Does Dpc affect blood pressure?

A: Official safety data reports cardiac adverse reactions such as tachycardia (fast heart rate) and palpitations, stemming from the decongestant component. Furthermore, the use of Dpc is restricted in patients with severe uncontrolled hypertension (high blood pressure) or severe coronary artery disease.


Q: Can Dpc be taken with acid reflux medications?

A: The official regulatory documentation requires the separation of Dpc and antacids by four hours to maintain drug absorption. Interaction protocols for other classes of acid reflux medications are not specified in the regulatory summary.


Q: What types of food or drinks should be avoided while taking Dpc?

A: Official administration instructions mandate that Dpc must be taken with a meal. Specific regulatory warnings note that consuming Grapefruit Juice should be avoided because it can interfere with how the body metabolizes the drug.


Q: Are there different strengths or forms of Dpc available?

A: Dpc is available for oral use in several dosage forms, including an oral liquid (syrup or suspension), a tablet, and a capsule. The official drug summary details the available forms, but information on different dosage strengths is not included.

How should Dpc be stored and disposed of?

How to Store and Dispose of DPC

The storage and disposal instructions for DPC are defined by regulatory documents to protect the stability of its multi-component formulation and ensure safety.

Official Storage Requirements

DPC is generally required to be stored at controlled room temperature (20 C to 25 C), away from excessive heat, light, and moisture. The medicine must be kept in its original container with the closure tightly closed to maintain its integrity.

Handling and Safety

Condition Requirement
Freezing Do not freeze (especially oral liquid forms).
Child Safety Keep out of the reach and sight of children.

Disposal Instructions

Unused or expired DPC must be disposed of according to local regulations to prevent accidental exposure and environmental contamination. The medicine must not be flushed down the toilet or thrown into the household trash unless the regulatory label explicitly instructs this action.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Dpc found in:

A-Z Index: